Discussion
The safest and most optimal transfusion threshold for geriatric trauma patients has been widely debated. Geriatric patients have a higher risk of coronary artery disease and other comorbidities which increase their risk of cardiovascular complications.7 Recommendations from the ASA Task Force on Perioperative Blood Management suggest a restrictive transfusion strategy may be safely used but were unable to recommend a specific universal trigger.9 Guidelines from the American Academy of Orthopedic Surgeons support a blood transfusion threshold of no higher than 8 g/dL in asymptomatic patients with postoperative hip fracture.10 Similarly, recent guidelines from the Association for the Advancement of Blood and Biotherapies recommend a red blood cell (RBC) transfusion threshold of 7 g/dL, but clinicians may choose a threshold of 7.5 g/dL in patients undergoing cardiac surgery and 8 g/dL in patients undergoing orthopedic surgery, or those with cardiovascular disease.11 There is no strong biological basis though, suggesting different effects with a threshold of 7 g/dL versus 8 g/dL in most populations, although randomized controlled trial (RCT) evidence is not available for all patient categories. These recommendations from many different governing bodies may encourage clinicians to transfuse patients if Hgb levels fall below 8 g/dL. Conversely, data from RCTs recommend transfusions in asymptomatic patients be held unless Hgb levels fall below 7 g/dL.12 13 This information leaves clinicians challenged with when to actually transfuse blood based on Hgb values if a patient has no other indications for transfusions. In this large, retrospective study, we observed a higher prevalence of adverse outcomes in geriatric patients with isolated hip fracture aged 79 years and older, who sustained an Hgb value of ≤7.1 g/dL. There was no difference in adverse outcomes in those aged 60–78 years who sustained an Hgb value of ≤7.1 g/dL. This supports the evidence for restrictive transfusion strategies in most geriatric patients but could imply the need for age-based transfusion protocols.
We used a composite endpoint to characterize adverse events which consisted of MI, ischemic stroke, new-onset cardiac arrhythmia, and death. Each of these conditions has been associated with anemia in the perioperative setting. The most common adverse outcome observed in our cohort was new-onset cardiac arrhythmia. Anemia has been previously shown to be a predictor of new-onset atrial fibrillation in non-cardiac surgery.14
Our threshold for Hgb where adverse events became more common was identified using CART analysis, a useful method for identifying thresholds with continuous data where two mutually exclusive groups can be formed. Subgroups were identified and groups were formed based on lowest Hgb and age where adverse outcomes were most prevalent. The group at greatest risk were those with an Hgb ≤7.1 g/dL, age >79 years and ASA score >3. This Hgb value of 7.1 g/dL is consistent with restrictive transfusion policies that are instituted at many centers. In contrast, patients who were greater than age 79 years had an alarmingly high rate of adverse outcomes when Hgb fell below 7.1 g/dL (approximately a 3.5-fold increase). Strong efforts should be taken to avoid anemia in this subpopulation.
Interestingly, our primary outcome may have been influenced by the use of RBC transfusions. Specifically, differences in risk were observed based on our identified Hgb threshold (≤7.1) and receipt of a transfusion. The highest risk was noted in patients with Hgb ≤7.1 who were not transfused. Although this was not statistically significant, this is likely due to the small number of patients in this cohort (n=6). The next highest-risk group was patients with Hgb ≤7.1 who were transfused (OR=4.8), but the group consisting of patients with Hgb >7.1 who received transfusions was also significant (OR=2.6). These data highlight the potential complications of liberal transfusion thresholds. We think a prospective study would better evaluate this relationship.
The optimal Hgb threshold for RBC transfusion in patients with hip fracture is unknown. One systematic review evaluated 10 trials involving 3968 patients who underwent orthopedic surgery (eg, hip fracture, hip or knee arthroplasty).15 They demonstrated that a restrictive strategy (mostly Hgb <8 g/dL) was associated with an increased risk of cardiovascular events compared with a more liberal transfusion strategy (mostly Hgb >10 g/dL); Risk ratio=1.51 (1.08 to 2.1)). Subgroup analysis revealed this risk was most evident in patients who underwent hip fracture surgery versus elective arthroplasty (p=0.02 vs. p=0.07). A second systematic review evaluated restrictive versus liberal blood transfusion strategies in nine studies of patients specifically with hip fractures (n=3575).16 In this analysis, there was no difference reported in mortality, but substantial variation existed with morbidity endpoints. Specifically, a restrictive transfusion threshold (which was defined as mostly an Hgb level of 8 g/dL or symptomatic anemia) was associated with higher rates of acute coronary syndromes, but a liberal transfusion threshold increased the risk of cerebrovascular accidents. It was concluded that clinicians adopt different transfusion strategies according to patient-specific scenarios rather than a transfusion trigger. A large study by Amin et al examined patient outcomes and blood utilization after instituting a restrictive transfusion protocol using an Hgb threshold of <7 g/dL and whether clinical outcomes were similar compared with a historical threshold of <8 g/dL.17 There were 498 patients included and a significant decrease in transfusions was noted (51% vs. 33%, p<0.001). There was no difference in mortality, but cardiac morbidity was significantly lower with the restrictive strategy (22% vs. 12%, p=0.004). This difference remained significant on multivariate analysis (OR (95% CI)=0.45 (0.27 to 0.75)). Last, a large RCT compared a liberal transfusion strategy (Hgb threshold of 10 g/dL) with a restrictive strategy (Hgb <8 g/dL) on the incidence of death or an inability to walk across a room at 60 days after hip fracture surgery.13 There were no differences noted between groups suggesting transfusions may be withheld in asymptomatic higher-risk patients. Collectively, these data illustrate the challenges in applying these data to the bedside given the heterogeneity in the study definitions (eg, thresholds for each transfusion strategy) and variance in the outcomes observed.
There are several limitations which should be acknowledged. First, this was a retrospective study so typical limitations inherent with this design would apply. Second, there was no transfusion protocol in place at either institution; thus, different transfusion triggers were used throughout the study period. Confounding by indication would therefore exist. Next, transfusion-related adverse effects were not analyzed (eg, infectious complication, acute lung injury, etc) which would provide a more global assessment of risks and benefits of transfusion practices. Finally, these results may not be generalizable given that all patients with hip fracture were admitted to the trauma service with a well-established geriatric (G60) program.18 Strengths of this study were the large sample size of 935 patients from two trauma centers committed to geriatric trauma. Lastly, the thresholds used to identify high-risk groups were formed using a multivariate statistical approach rather than predetermined operational definitions.
In conclusion, adverse events were more prevalent when Hgb values fell below 7.1 g/dL. This risk was also age related with higher adverse outcomes occurring in patients who were greater than age 79 years. Clinicians should consider appropriate interventions to maintain Hgb values above this level. It is possible that transfusion triggers should vary based on age group. When controlling for blood transfusions, we noted that adverse outcomes could be mediated by blood transfusions, leading us to question the use of early transfusion thresholds. Future studies are needed to refine transfusion thresholds in high-risk subpopulations including age, fracture patterns, and surgical approaches.